You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Though it is unclear whether the virus became pathogenic before or after the jump from animals to humans, genomic features point to a natural source for the COVID-19 coronavirus.
The US Court of Appeals for the Federal Circuit affirmed a lower-court decision in favor of Illumina, which Scripps had sued over marketing of bead-based microarrays.
Researchers saw signs of an unreported Zika virus outbreak in Cuba in 2017, well after the documented decline in new cases in Brazil and other parts of the world.
ScienceInsider reports Floyd Romesberg has been forced out from the Scripps Research Institute.
In PNAS this week: role for exosomes in neuronal circuit development, tuberculosis pathogen enzymes, and more.
An analysis of B cell adaptive immune receptor sequences in 10 individuals uncovered exceptionally diverse antibody repertoires with a subset of shared antibody clonotypes.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.
There are some deep divisions between the three main databases, some due to competitive pressures and others because of the nature of metabolomics.
In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.
Two research teams find a role for PIEZO2 in touch sensitivity after injury and inflammation.
Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.
Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.
A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.
In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.